Normal tissue protection in cancer therapy - Progress and prospects

Pathirissery Uma Devi

Research output: Contribution to journalReview article

45 Citations (Scopus)

Abstract

Normal tissue tolerance is a major dose-limiting factor in radiotherapy and chemotherapy of cancer. During the past few decades several investigations have been directed toward increasing normal tissue tolerance by using chemical protectors against radiation and drug toxicity. WR-2721, the phosphorylated aminothiol, synthesized in the 1960s, has been hailed as the best chemical protector discovered so far. But its systemic toxicity after repeated administration in cancer patients during clinical trials has been a deterrent against its acceptance in routine radiotherapy, though more encouraging results have been reported with chemotherapy. The 1980s found a surge of activity in the field of chemical protection research, which has resulted in the discovery of many non-thiol protectors, particularly the biological response modifiers and antioxidants. It has also been found that protection by WR-2721 can be improved and its toxicity reduced by combination with some low potent protective chemicals. This review analyzes the major reports on chemical protectors published during the past ten years.

Original languageEnglish
Pages (from-to)247-252
Number of pages6
JournalActa Oncologica
Volume37
Issue number3
DOIs
Publication statusPublished - 15-07-1998
Externally publishedYes

Fingerprint

Amifostine
Radiotherapy
Drug Therapy
Immunologic Factors
Drug-Related Side Effects and Adverse Reactions
Neoplasms
Antioxidants
Clinical Trials
Radiation
Therapeutics
Research

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Devi, Pathirissery Uma. / Normal tissue protection in cancer therapy - Progress and prospects. In: Acta Oncologica. 1998 ; Vol. 37, No. 3. pp. 247-252.
@article{8a746cdbe056443490334040c8f0250c,
title = "Normal tissue protection in cancer therapy - Progress and prospects",
abstract = "Normal tissue tolerance is a major dose-limiting factor in radiotherapy and chemotherapy of cancer. During the past few decades several investigations have been directed toward increasing normal tissue tolerance by using chemical protectors against radiation and drug toxicity. WR-2721, the phosphorylated aminothiol, synthesized in the 1960s, has been hailed as the best chemical protector discovered so far. But its systemic toxicity after repeated administration in cancer patients during clinical trials has been a deterrent against its acceptance in routine radiotherapy, though more encouraging results have been reported with chemotherapy. The 1980s found a surge of activity in the field of chemical protection research, which has resulted in the discovery of many non-thiol protectors, particularly the biological response modifiers and antioxidants. It has also been found that protection by WR-2721 can be improved and its toxicity reduced by combination with some low potent protective chemicals. This review analyzes the major reports on chemical protectors published during the past ten years.",
author = "Devi, {Pathirissery Uma}",
year = "1998",
month = "7",
day = "15",
doi = "10.1080/028418698429531",
language = "English",
volume = "37",
pages = "247--252",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "3",

}

Normal tissue protection in cancer therapy - Progress and prospects. / Devi, Pathirissery Uma.

In: Acta Oncologica, Vol. 37, No. 3, 15.07.1998, p. 247-252.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Normal tissue protection in cancer therapy - Progress and prospects

AU - Devi, Pathirissery Uma

PY - 1998/7/15

Y1 - 1998/7/15

N2 - Normal tissue tolerance is a major dose-limiting factor in radiotherapy and chemotherapy of cancer. During the past few decades several investigations have been directed toward increasing normal tissue tolerance by using chemical protectors against radiation and drug toxicity. WR-2721, the phosphorylated aminothiol, synthesized in the 1960s, has been hailed as the best chemical protector discovered so far. But its systemic toxicity after repeated administration in cancer patients during clinical trials has been a deterrent against its acceptance in routine radiotherapy, though more encouraging results have been reported with chemotherapy. The 1980s found a surge of activity in the field of chemical protection research, which has resulted in the discovery of many non-thiol protectors, particularly the biological response modifiers and antioxidants. It has also been found that protection by WR-2721 can be improved and its toxicity reduced by combination with some low potent protective chemicals. This review analyzes the major reports on chemical protectors published during the past ten years.

AB - Normal tissue tolerance is a major dose-limiting factor in radiotherapy and chemotherapy of cancer. During the past few decades several investigations have been directed toward increasing normal tissue tolerance by using chemical protectors against radiation and drug toxicity. WR-2721, the phosphorylated aminothiol, synthesized in the 1960s, has been hailed as the best chemical protector discovered so far. But its systemic toxicity after repeated administration in cancer patients during clinical trials has been a deterrent against its acceptance in routine radiotherapy, though more encouraging results have been reported with chemotherapy. The 1980s found a surge of activity in the field of chemical protection research, which has resulted in the discovery of many non-thiol protectors, particularly the biological response modifiers and antioxidants. It has also been found that protection by WR-2721 can be improved and its toxicity reduced by combination with some low potent protective chemicals. This review analyzes the major reports on chemical protectors published during the past ten years.

UR - http://www.scopus.com/inward/record.url?scp=0031750569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031750569&partnerID=8YFLogxK

U2 - 10.1080/028418698429531

DO - 10.1080/028418698429531

M3 - Review article

VL - 37

SP - 247

EP - 252

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 3

ER -